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Objectives We analyzed the infection burden associated with the implantation of cardiac implantable electrophysiological
devices (CIEDs) in the United States for the years 1993 to 2008.
Background Recent data suggest that the rate of infection following CIED implantation may be increasing.
Methods The Nationwide Inpatient Sample (NIS) discharge records were queried between 1993 and 2008 using the 9th
Revision of the International Classification of Diseases (ICD-9-CM). CIED infection was defined as either: 1) ICD-9
code for device-related infection (996.61) and any CIED procedure or removal code; or 2) CIED procedure code
along with systemic infection. Patient health profile was evaluated by coding for renal failure, heart failure, respi-
ratory failure, and diabetes mellitus. The infection burden and patient health profile were calculated for each
year, and linear regression was used to test for changes over time.
Results During the study period (1993 to 2008), the incidence of CIED infection was 1.61%. The annual rate of infec-
tions remained constant until 2004, when a marked increase was observed, which coincided with an increase in
the incidence of major comorbidities. This was associated with a marked increase in mortality and in-hospital
financial charges.
Conclusions The infection burden associated with CIED implantation is increasing over time and is associated with prolonged
hospital stays and high financial costs. (J Am Coll Cardiol 2011;58:1001–6) © 2011 by the American College
of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.033Implantation of cardiac implantable electrophysiological
devices (CIEDs), which include permanent pacemakers
(PM) and implantable cardioverter-defibrillators (ICDs),
has dramatically increased over the past several years (1–3).
This is largely due to the expanded indications for CIED
implantation based on the results of large clinical trials of
ICDs for primary prevention as well as the aging of the
general population (4–6). Infection associated with CIEDs
s a serious complication with high morbidity and mortality
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2011, accepted April 21, 2011.(7–9). Previous studies have suggested that the number of
infections associated with CIEDs is increasing (10,11). We
sought to analyze the historical trends for CIED infection
in the United States over 16 years and evaluate the impli-
cations of these trends.
Methods
The Nationwide Inpatient Sample (NIS) discharge records
were queried to identify demographic (e.g., age, sex), health
profile/risk (incidence and severity of comorbidities, mor-
tality), and health economic (length of stay, procedural costs
and charges) data for PM and ICD patients between 1993
and 2008 using the International Classification of Diseases-
9th Revision-Clinical Modification (ICD-9-CM). Specifi-
cally, procedures were identified by the ICD-9-CM codes
that identified both primary and revision CIED procedures:
Primary PM: 37.80–83, 00.50; Primary ICD: 37.94, 37.96,
00.51; PM Removal: 37.79, 37.85–87, 37.89, 00.53; ICD
Removal: 37.98, 00.54. Revision procedures include pulse
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device upgrades to either dual-
chamber or cardiac resynchroni-
zation therapy devices. During
this time period, the ICD-9-CM
codes for these procedures have
been consistent, thereby allowing
the analysis of longitudinal
trends in the data for prevalence
of device implantation.
Patients with a CIED-related
infection, either pocket infection
or systemic infection including
lead-associated endocarditis, were
identified in 1 of 2 ways: 1) an
ICD-9-CM diagnosis code for
device-related infection (996.61)
along with any CIED primary
procedure or removal code; or 2)
a CIED removal code (37.77, 37.7, 37.89, 37.99) along
with evidence of systemic infection such as sepsis (038 or
785.59), bacteremia (790.7), or fever (780.6). Patient health
profile was evaluated by coding for renal failure, heart failure,
espiratory failure, and diabetes mellitus.
The CIED infection burden was calculated by dividing
he number of device-related infections by the correspond-
ng number of primary or revision procedures. Analyses of
he NIS records with the relevant surgical codes were
onducted using SAS (version 9.2, Cary, North Carolina).
ospital charges over the time period of this study were
djusted to the equivalent amount in January 2009 using
Abbreviations
and Acronyms
CI  confidence interval
CIED  cardiac implantable
electrophysiological device
HCUP  Healthcare Cost
and Utilization Project
ICD  implantable
cardioverter-defibrillator
ICD-9-CM  International
Classification of Diseases-
9th Revision, Clinical
Modification
NHDS  National Hospital
Discharge Survey
NIS  Nationwide Inpatient
Sample
PM  pacemaker
Figure 1 Annual Number of PM and ICD Implantations: 1993 to
Between 1993 and 2008, overall cardiac implantable electrophysiological device (
Pacemaker (PM) implantation increased by 45%, whereas implantable cardioverterthe consumer price index for medical services published by
the Bureau of Labor Statistics. Hospital cost estimates were
converted from hospital charges by the “cost-to-charge”
ratio provided by the HCUP. If a cost-to-charge conversion
ratio was not available for a particular hospital, the average
conversion ratio for hospitals in the same sampling strata
was used. The sampling weights and the stratified sampling
design of the NIS were taken into consideration when
computing summary statistics and standard errors of these
estimates. The number of surgeries performed for a partic-
ular demographic group is a positive integer and is assumed
to follow a Poisson distribution. A regression model was
used to estimate the surgery and infection rate, normalized
by the size of the population, and evaluation of the calendar
year trend. The surgery rate was adjusted by age, sex, race,
and census regions to accommodate differences in the preva-
lence among demographic subpopulations. The infection bur-
den and patient health profile were calculated for each year,
and linear regression was used to test for changes over time.
Results
Trends in CIED infection. Between 1993 and 2008, over
4.2 million primary implantations of PM (3,204,700 re-
cords) and ICD (1,124,000 records) were identified using
ICD-9-CM procedure codes. We found that the incidence
of CIED implantation increased an average of 4.7% annu-
ally, and the overall CIED implantation increased by 96%
from 1993 to 2008 (Fig. 1). The majority of this increase
was due to the large increase in ICD implantation (504%) as
pacemaker implantation increased by 45% during this time
8
implantation increased by 96% (an average of 4.7%/year).
illator (ICD) implantation increased by 504%.200
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implantations (Fig. 2).
During the study period (1993 to 2008), approximately 69,000
patients were treated for CIED infection (incidence  1.61%).
he incidence of infection increased by 210%, from 2,660 cases in
993 to 8,230 cases in 2008. The annual rate of infections
emained fairly constant until 2004 when a marked increase was
bserved. The rate of infection increased significantly, from 1.53%
n 2004 to 2.41% in 2008 (p  0.001) (Fig. 3).
The rates of CIED infection from 1993 to 2008, cate-
orized by patient demographics (age, sex, race), showed
hat the highest infection rates occurred in patients that
Figure 2 PMs and ICDs as a Percentage of
All CIED Implantations: 1993 Versus 2008
The importance of the rise in ICD implantations is highlighted by the
increase in 2008 to 35% of all CIED implants. Abbreviations as in Figure 1.
Figure 3 Rate of CIED Infection
The annual rate of cardiac implantable electrophysiological device (CIED) infection
The infection rate increased from 1.53% in 2004 to 2.41% in 2008 (p  0.001).ere white (82%), male (67%), and over the age of 65 years
64%) (Fig. 4).
ole of comorbidities in CIED infection. The incidence
f 4 major comorbidities (renal failure, respiratory failure,
eart failure, and diabetes) in patients with CIED infection
emained fairly constant from 1993 through 2004 when a
arked increase was observed (Fig. 5). In addition, the risk
f mortality significantly increased in patients with respira-
ory failure (odds ratio: 13.58; 95% confidence interval [CI]:
2.88 to 14.3), renal failure (odds ratio: 4.28; 95% CI: 4.04
o 4.53), heart failure (odds ratio: 2.71; 95% CI: 2.54 to
.88) but decreased slightly in patients with diabetes (odds
atio: 0.91; 95% CI: 0.86 to 0.96) (p  0.001).
inancial burden and mortality rates associated with
IED infection. In 1993, in-hospital charges for CIED
nfection were approximately $75,000 and increased to over
146,000 by 2008, an increase of 47% per decade (Fig. 6).
npatient mortality associated with CIED infection aver-
ged 4.39%, but increased from 2.91% in 1993 to 4.69% in
008, representing an increase of 1% per decade. During the
tudy period, hospitalization remained constant and aver-
ged 13.8 days.
iscussion
n analysis of the NIS demonstrates that during the study
eriod 1993 to 2008, the national CIED infection burden
ncreased. Specifically, there was an increase in the inci-
ence of CIED infection along with an increase in inpatient
ned fairly constant until 2004 when there was a marked increase.remai
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comorbidities associated with prolonged hospital stays and
an increase in the utilization of medical resources reflected
by an increase in hospital charges.
Figure 4 Distribution of CIED Infection Based on Patient Age
Cardiac implantable electrophysiological device (CIED) infections were more comm
Figure 5 Incidence of Comorbidities in Patients With CIED Infe
The incidence of 4 major comorbidities (renal failure, respiratory failure, heart failu
observed. This paralleled both the observed increase in implantable cardioverter-d
electrophysiological device.Over the past 20 years, the number of patients with
CIEDs has dramatically increased (1–3). Among Medicare
beneficiaries, the rate of cardiac device implantation in-
creased by 42% between 1990 and 1999 (10). Our initial
bserved in elderly patients.
d diabetes) remained fairly constant until 2004 when a marked increase was
ator implantation and the increased infection rate. CIED  cardiac implantableonly oction
re, an
efibrill
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of insurance coverage, showed a 30% increase in the primary
pacemaker implantation rate of 50.0 per 100,000 persons of
population in 1993 to 65.1 per 100,000 in 2006 (1). ICD
implantation rate increased more rapidly during this period
of time. In 1993, the ICD implantation rate was 6.1 per
100,000 persons of population and rose dramatically to 46.2
per 100,000 persons of population by 2006, an increase of
over 500%.
The present study demonstrates that overall CIED im-
plantation increased by 96%. Most of this increase was due
to the marked increase in ICD utilization. By the end of the
study period, ICDs represented 35% of all devices. It is
estimated that CIED utilization will continue to grow over
the next several years due to expanded Medicare coverage
for these devices (12). Complications of CIED implantation
are an important consideration in patient selection for
CIED implantation. Interestingly, immediate post-
procedural complications related to CIED implantation
have decreased. Al-Khatib et al. (13) reported that the rate
of post-procedural complications in CIED recipients fell
between 2002 and 2005. The fall in procedure-related
complications may be due to operator experience, improved
device technology, and patient selection (13–15). Unfortu-
nately, the corresponding risk of device-related infection has
not changed during the same period of time (8,10,11,16,17).
Previous studies have attempted to define the burden of
CIED infection. Voigt et al. (11) analyzed records from the
National Hospital Discharge Survey (NHDS) between
Figure 6 In-Hospital Charges Associated With CIED Infection (I
The increased infection burden was associated with increased financial costs and
increased to over $146,000 by 2008, which represents an increase of 47% decad1996 and 2006. Analysis of the NHDS database showedthat device-related infection in CIED patients increased out
of proportion to the overall increase in device utilization
during the period 1996 to 2006. The NIS database, ana-
lyzed in the present study, samples about 25 times more
discharge records than the NHDS and tends to sample data
from larger institutions. This may account for some varia-
tion between the 2 surveys.
Results from our analysis of the NIS show that the annual
incidence of CIED infection increased by 210% to 2.41% in
2008 (p  0.0001). Our data may more accurately reflect
the true CIED infection burden since previous studies may
have included patients with infections of other cardiac
devices such as prosthetic heart valves and not CIEDs alone.
We required a CIED procedure code along with the 996.61
code to define a CIED infection. We also defined a
device-related infection as evidence of sepsis or bacteremia
along with a CIED removal code. This study and others
highlight the disturbing trend of increasing CIED infection
(8–11,16,17).
CIED infection is associated with high patient morbidity
and a mortality rate of up to 18% (8,9,16,17). The financial
burden of CIED infection is reflected by the 47% per
decade increase in hospital charges related to CIED infec-
tion. By 2008, hospital charges were over $146,000. These
expenditures do not include the additional costs of pro-
longed recovery and rehabilitation following treatment of
the infection. Therefore, CIED infection has enormous
economic implications (18).
The reason for the increasing rate of CIED infection
ion Adjusted to 2009)
inpatient mortality. In-hospital charges
D  cardiac implantable electrophysiological device.nflat
higher
e. CIEdespite a decrease in overall device-related complications is
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increasing numbers of ICD and cardiac resynchronization
therapy devices whose longevity is significantly lower than
PM. It is estimated that over 70% of ICD recipients will
require device replacement surgery (19). Device replacement
surgery is associated with an increased risk of infection
(19,20). There may be an increasing burden of device
replacements in the overall CIED population since ICDs
now represent 35% of all implantations.
Patient characteristics, in addition to replacement bur-
den, likely contribute to the increasing infection burden. It
is well known that patients with chronic renal insufficiency
and diabetes mellitus are at particular risk for CIED
infection (21). Our analysis showed that there is an increas-
ing incidence of these risk factors in CIED patients.
Although the present study shows that the incidence of
comorbidities in patients who present with CIED infection
is increasing, it does not address the important question of
what specific risk factors predict CIED infection or what
factors might mitigate this issue. However, it does appear
that patients with multiple comorbidities are at particular
risk. Further study of these critical issues is important.
Conclusions
The infection burden associated with CIED implantation is
increasing over time. This is likely due to expanding ICD
indications and the increasing comorbidities in the CIED
population. Infection is associated with prolonged hospital
stays and high financial costs. Further investigation into the
risk factors for CIED infection is warranted.
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